Literature DB >> 2283892

Simplified long term large scale production of highly active human LAK cells for therapy.

P Wersäll1, G Masucci, P Pihlstedt, H Wigzell, H Mellstedt.   

Abstract

Cells obtained by leukapheresis and separated without or with a Ficoll-Isopaque (FIP) gradient were cultured for 4 or 20 days to determine whether a more effective LAK cell population could be obtained compared to LAK cells generated by the commonly used method (FIP separated cells cultured for 4 days). After leukapheresis the cells were separated on a FIP gradient (FIP cells) or only washed to minimize platelet contamination (non-FIP cells). In some experiments, the cells were also pretreated with phenylalanine-methylester (PheOMe) to reduce monocytes. After culturing for 20 days in the presence of IL-2 (100 BRMP U ml-1) a significantly higher total number of CD3+ and CD56+ cells was noted in the non-FIP fraction compared to the FIP fraction. The total lytic activity of non-FIP cells (LU/tot. no. of cells) against Daudi targets after 4 days of culture was 11,820 +/- 624 versus 4770 +/- 550 of FIP cells (P less than 0.05). After 20 days of culture the non-FIP fraction exhibited a higher cytotoxic activity than the FIP cell fraction, 76,291 +/- 20,053 compared to 7169 +/- 1148 LU (P less than 0.05). Pretreatment of the cells with PheOMe induced a significantly more effective cytotoxic population when cultured for 4 days. However, at 20 days PheOMe did not enhance the LAK cell activity. Large scale production of LAK cells can be accomplished without FIP separation with an increased cell yield and cytotoxicity compared to FIP separated cells both in short and long time cultures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2283892     DOI: 10.1007/bf02987104

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  23 in total

1.  Generation of human LAK cells in tissue culture bags using recombinant IL-2 and serum free medium. Effects of pretreatment with phenylalanine-methylester.

Authors:  P Wersäll; G Masucci; P Pihlstedt; I Cotgreave; B Tribukait; M Ullberg; H Wigzell; H Mellstedt
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

2.  Long-term culture of LAK cells: expansion and activation signals.

Authors:  A C Ochoa; R J Migliori; B J Alter; P M Sondel; R L Simmons; F H Bach
Journal:  Prog Clin Biol Res       Date:  1987

3.  Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

Authors:  M Hoyer; T Meineke; W Lewis; B Zwilling; J Rinehart
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

4.  Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1.

Authors:  R Schwab; M K Crow; C Russo; M E Weksler
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

6.  Increased cytotoxicity and CD16 (Leu 11) expression in long-term, IL-2-activated human peripheral blood mononuclear cells.

Authors:  E R Podack; K O Penichet; B Y Lin; J W Chiao; A Mittelman
Journal:  Blood Cells       Date:  1987

7.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

8.  Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Authors:  M R Shalaby; B B Aggarwal; E Rinderknecht; L P Svedersky; B S Finkle; M A Palladino
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Authors:  R J Melder; T L Whiteside; N L Vujanovic; J C Hiserodt; R B Herberman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

10.  Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

Authors:  A C Ochoa; G Gromo; B J Alter; P M Sondel; F H Bach
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.